This is our second update on the litigation (you can see the prior analyses here and here, in addition to a parallel post on our companion...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Litigation Spotlight
-
-
Since our prior article on the litigation between Amgen and Hospira over Hospira’s proposed biosimilar to Amgen’s Epogen®, there have...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
This article provides an update on our prior analysis of the infliximab litigation involving Janssen Biotech, Inc. (“Janssen”),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Introduction and Background The Apotex filgrastim/pegfilgrastim biosimilar litigation was the first biosimilar litigation where the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Editors’ Note: Although the BPCIA was enacted seven years ago, to date, only four biosimilar products have been approved by the FDA, and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]